An experienced team delivering anti-cancer therapeutics with breakthrough potential

Karus Therapeutics is a clinical-stage biopharmaceutical company. We are developing precision medicines for cancer.

Our team

Our highly experienced management team has a track record of scientific and clinical excellence in small-molecule drug design and development. Our programs are underpinned by a broad, wholly-owned, intellectual property estate.

Our approach

Our orally-active small-molecule drugs have been designed and developed to be highly-selective therapies for cancer patients with unmet medical needs and limited treatment options.

Clinical Pipeline

We have completed a Phase I study for KA2237, with positive results. Data for KA2237 shows an overall response rate of 37 % in 19 evaluable patients with relapsed/refractory B cell lymphoma.

We are concluding a Phase I study for KA2507 at MD Anderson Cancer Centre, Houston. In addition, KA2507 is being progressed into a Phase II clinical study at the CRUK-UCL Cancer Trials Centre in London.


We invest in research and development of the highest quality and collaborate with leading academic centers of excellence. Our R&D program program is focused on a new generation of brain-penetrant small molecules targeting glioblastoma and other indications.

Strategic partnering

We seek strategic collaborations with leading companies who are commercialising innovative anti-cancer therapeutics.

For our clinical trials, we are collaborating with The University of Texas MD Anderson Cancer Center and the CRUK-UCL Cancer Trials Centre, London.


We are supported by a syndicate of world-class life science investors from the US and Europe.